论文部分内容阅读
目的：评价基因工程人白细胞介素－２（ｒｉＬ－２）治疗恶性浆膜腔积液疗效。方法：作者对接受ｒｉＬ－２治疗的５７例恶性浆膜腔积液进行了回顾性研究。其中恶性胸膜腔积液５２例（Ａ组），恶性腹膜腔积液４例（Ｂ组），恶性心包腔积液１例（Ｃ组），Ａ、Ｂ、Ｃ组腔内注射剂量分别为３０～５０万单位、５０～１００万单位、１００万单位，每周注射１～２次，连续作２～４周。结果：Ａ组ＣＲ率为５１．９％（２７／５２），ＰＲ率为３０．７％（１６／５２），总有效率（ＣＲ＋ＰＲ）为８２．６％（４３／５２），癌细胞阴转率为７４．４％（３２／４３）；Ｂ组１例达ＰＲ，有效率为２５％（１／４）；Ｃ组１例治疗后达ＣＲ。主要的不良反应为发热、胸痛、胃肠道反应，但均较轻。结论：白细胞介素－２具有疗效好、不良反应低的特点
Objective: To evaluate the efficacy of genetically engineered human interleukin-2 (riL-2) in the treatment of malignant serous effusions. Methods: The authors retrospectively studied 57 cases of malignant serous effusions treated with riL-2. Among them, 52 cases of malignant pleural effusion (group A), 4 cases of malignant peritoneal effusion (group B), 1 case of malignant pericardial effusion (group C), and 30 cases of intracavity injection of group A, B, and C respectively. ~ 500,000 units, 50 to 1 million units, 1 million units, 1 to 2 injections per week for 2 to 4 consecutive weeks. Results: The CR rate in group A was 51.9% (27/52), the PR rate was 30.7% (16/52), and the total effective rate (CR+PR) was 82.6% (43/52). The conversion rate was 74.4% (32/43); in group B, 1 case had PR, and the effective rate was 25% (1/4); in group C, 1 case had CR after treatment. The main adverse reactions were fever, chest pain, and gastrointestinal reactions, but all were mild. Conclusion: Interleukin-2 has good curative effect and low adverse reaction